Aurobindo Pharma Limited (AUROPHARMA)
Press Release
Press Release - Q2FY27
- Revenue 10,263 Cr +24% y-y; EBITDA 2,156 Cr +29% y-y (margin 21.0%, +75 bps); PAT 1,124 Cr +33% y-y
- US revenue grew 25% y-y to 4,555 Cr driven by base growth and new launches
- Europe revenue up 27% y-y to 3,161 Cr; Growth Markets +16% y-y to 1,026 Cr
- API revenue increased 21% y-y to 1,162 Cr; R&D spend at 376 Cr this quarter
- Declared interim dividend of ₹7.0 per share
- Strong free cash flow of USD 146 million; net cash position USD 189 million as of Sep 30, 2026
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 AUROPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add AUROPHARMA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Aurobindo Pharma Limited
Important.
The summary above is generated automatically from Aurobindo Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.